89bio Inc

89bio, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. Its product pipeline includes pegozafermin, FGF21, NASH, and SHTG. The company was founded in January 2018 and is headquartered in San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

89bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. Its product pipeline includes pegozafermin, FGF21, NASH, and SHTG. The company was founded on January 18, 2018 and is headquartered in San Francisco, CA.

SAN FRANCISCO, Feb. 24, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Company's Management will provide a corporate update and participate in one-on-one investor meetings at the Raymond James 42nd Annual Institutional Investors Conference on Wednesday, March 3, 2021 at 12:30 PM ET.

89bio to Present at the 42nd Annual Raymond James Institutional Investors Conference

BIO89-100 is lead and only molecule targeting NASH with superior early-stage data. Among its peer group, molecule is well differentiated.

89bio: NASH Drug Developer With Differentiated Profile

SAN FRANCISCO, Jan. 04, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Rohan Palekar, the company's Chief Executive Officer, will provide a corporate update at the virtual H.C. Wainwright BioConnect 2021 Conference to be held January 11-14, 2021.

89bio to Participate in the H.C. Wainwright BioConnect 2021 Conference

SAN FRANCISCO, Nov. 24, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Rohan Palekar, the company's Chief Executive Officer, will participate in 1x1 meetings with investors at the Piper Sandler 32nd Annual Virtual Healthcare Conference on Wednesday, December 2, 2020. The conference will take place December 1-3, 2020. An archived webcast of the fireside chat is accessible in the investor section of 89bio's website.

89bio To Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference

– Data demonstrated compelling efficacy profile and favorable tolerability with weekly and every two-week dosing –

89bio Presents Updated Clinical Data from Positive Phase 1b/2a Study of BIO89-100 in NASH at AASLD's The Liver Meeting® 2020

– Updated clinical data from BIO89-100 's Phase 1b/2a NASH trial to be presented as a late-breaking poster at upcoming AASLD Liver Meeting –

89bio Reports Third Quarter 2020 Financial Results and Provides Corporate Update

SAN FRANCISCO, Sept.  28, 2020  (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Rohan Palekar, the company’s Chief Executive Officer, will present at the H.C. Wainwright 4th Annual NASH Investor Conference on Monday, October 5, 2020 at 11:30 AM ET.

89bio to Present at Upcoming Investor Conference

SAN FRANCISCO, Sept.  16, 2020  (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced the pricing of an upsized underwritten public offering of 3,300,000 shares of its common stock at a public offering price of $28.00 per share. 3,025,000 shares are being offered by 89bio, and 275,000 shares are being offered by a selling stockholder. The gross proceeds of the offering to 89bio, before deducting the underwriting discount and other offering expenses payable by 89bio, are expected to be approximately $84.7 million.  In addition, 89bio has granted the underwriters a 30-day option to purchase up to an additional 495,000 shares of common stock, at the public offering price, less the underwriting discounts and commissions. 89bio will not receive any proceeds from the sale of shares of the company’s common stock by the selling stockholder. The offering is expected to close on September 21, 2020, subject to the satisfaction of customary closing conditions.

89bio Announces Pricing of Upsized Public Offering of Common Stock

SAN FRANCISCO, Sept.  14, 2020  (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that it has commenced an underwritten public offering of 3,000,000 shares of its common stock, which includes 2,700,000 shares of the common stock offered by the company and 300,000 shares of the common stock offered by certain of the company’s stockholders. In addition, the company and a selling stockholder is expected to grant the underwriters of the offering an option for a period of 30 days to purchase up to an additional 175,000 shares of common stock and 275,000 shares of common stock, respectively, at the public offering price, less the underwriting discounts and commissions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

89bio Announces Proposed Public Offering of Common Stock

All dose groups achieved statistically significant reductions in liver fat, with relative reductions of up to 60% versus baseline and up to 70% versus placebo    

89bio Announces Positive Topline Results from its Phase 1b/2a Trial of BIO89-100 in NASH

SAN FRANCISCO, Sept.  13, 2020  (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB) today announced that the company plans to share topline safety, tolerability and efficacy data from its Phase 1b/2a study of BIO89-100 in NASH in a pre-market press release and webcast to be held on Monday, September 14, 2020.

89bio to Announce Topline Results from Phase 1b/2a Study of BIO89-100 in NASH

- Multi-center, randomized, double-blind, placebo-controlled study will evaluate the safety and efficacy of BIO89-100 administered weekly or every two weeks for 8 weeks - - Multi-center, randomized, double-blind, placebo-controlled study will evaluate the safety and efficacy of BIO89-100 administered weekly or every two weeks for 8 weeks -

89bio Initiates Phase 2 Trial of BIO89-100 in Patients with Severe Hypertriglyceridemia

- Topline results from BIO89-100’s Phase 1b/2a NASH trial are expected in Late Q3 to Early Q4 -

89bio Reports Second Quarter 2020 Financial Results and Provides Corporate Update

89bio (ETNB) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Earnings Season Could Be Great for 89bio (ETNB)

Arcturus Therapeutics

AvroBio Inc

Fulcrum Therapeutics Inc

Intercept Pharma

Let us take a look at some biotech stocks that are poised to beat on second-quarter earnings.

5 Biotech Stocks Set to Outpace Q2 Earnings Estimates

SAN FRANCISCO, July  13, 2020  (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, announced the closing of its upsized underwritten public offering of 3,047,040 shares of common stock, which includes the exercise in full by the underwriters of their option to purchase up to 397,440 additional shares of common stock, at a public offering price of $27.50 per share. The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by 89bio, were approximately $83.8 million. All of the shares were offered by 89bio.

89bio Announces Closing of Upsized Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares

89bio (ETNB) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

89bio (ETNB) Jumps: Stock Rises 6.9%

SAN FRANCISCO, June  04, 2020  (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced the appointment of Lota S. Zoth, CPA to its Board of Directors and as Chair of the Audit Committee. A veteran of the biopharmaceutical industry, Ms. Zoth brings more than 35 years of financial and strategic experience to her role.

89bio Appoints Veteran Finance Executive Lota Zoth to Board of Directors

- Topline results from BIO89-100’s Phase 1b/2a NASH trial are expected in 2H20 -

89bio Reports First Quarter 2020 Financial Results and Provides Corporate Update

- Closed enrollment in its Phase 1b/2a NASH trial with 98% of patients enrolled and delays initiation of its SHTG trial due to the COVID-19 pandemic; Reaffirms guidance for NASH trial topline data in 2H20 -

89bio Announces Closing of Enrollment in its Phase 1b/2a NASH Trial and Reports New Preclinical Data Confirming BIO89-100’s Mechanism of Action Via Potent FGF Receptor Agonism

SAN FRANCISCO, March  25, 2020  (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced the appointment of Steven Altschuler, M.D., as chairman of its board of directors. Dr. Altschuler currently serves as managing director of Healthcare Ventures at Ziff Capital Partners. He brings 20 years of experience growing healthcare organizations in business and leadership capacities.

News for 89bio Inc Stock (ETNB)